Mono Pharmacare Ltd (MONOPHARMA) — shareholding pattern, promoter holding, financials and share price
About Mono Pharmacare Ltd (MONOPHARMA)
Mono Pharmacare Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as MONOPHARMA and on the BSE under scrip code 78964. Its ISIN is INE0OIP01012.
Incorporated in 1994, Mono Pharmacare Ltd is in the business of distribution of Pharmaceutical items [1]
Mono Pharmacare Limited is engaged in the marketing and distribution of pharmaceutical products, operating since 1994. Their portfolio includes antibiotics, antifungals, skincare, and cardiac drugs, manufactured through contract partners.
The company transitioned from a partnership to a public limited entity in October 2022, indicating an organized structural evolution for better market access and capital acquisition.
Listed peers in Pharmaceuticals: Ishita Drugs & Industries Ltd, Cian Healthcare Ltd, Centuple Global Ltd, Rekvina Labs Ltd, Desh Rakshak Aushdhalaya Ltd, Zenith Health Care Ltd.
Valuation & Returns
At ₹10.8 a share, Mono Pharmacare Ltd (MONOPHARMA) was valued at a price-to-earnings ratio of 23.42x against an industry P/E of 36.41x and a price-to-book of 0.62x on a book value of ₹17.66 per share. Solomo computes return on equity of 2.67% and return on capital employed of 6.38% from filed results.
- P/E
- 23.42x
- Industry P/E
- 36.41x
- P/B
- 0.62x
- EPS (TTM)
- ₹1.75
- Book value / share
- ₹17.66
- ROE
- 2.67%
- ROCE
- 6.38%
- ROA
- 0.7%
- Debt / equity
- 1.76x
- Dividend yield
- 0%
- EBITDA margin
- 3.82%
- 52-week range
- ₹9.45 – ₹27.5
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Mono Pharmacare Ltd (MONOPHARMA) reported revenue of ₹166 crore and earnings per share of ₹0.2. That compares with revenue of ₹168 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹99 crore (consolidated).
| Metric | Mar 2023 | Mar 2023 6m | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 26.99 | 33 | 122 | 168 | 166 |
| Net profit (₹ cr) | 0.7 | 1 | 2 | 3 | 0 |
| EPS (₹) | - | 0.76 | 1.38 | 1.75 | 0.2 |
| Measure | 1Y |
|---|---|
| Sales growth | 37.60% |
| Profit growth | 26.42% |
| Stock price CAGR | -57% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 56.72% of Mono Pharmacare Ltd (MONOPHARMA). Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2023.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 56.72% | - | - | - | - |
| Sep 2025 | 56.72% | - | - | - | - |
| Mar 2025 | 56.72% | - | - | - | - |
| Sep 2024 | 56.72% | - | - | - | - |
| Mar 2024 | 56.72% | - | - | - | - |
| Dec 2023 | 56.72% | - | - | - | - |
| Sep 2023 | 56.72% | - | - | - | - |